Fig. 7: Seasonality of AEs related to asthma exacerbations and symptoms in paediatric patients within the PensieTinA-, RubaTinA-, VivaTinA-, CanoTinA- and NinoTinA-asthma trials41.
From: Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment
Number of patients aged 1–17 years with asthma or persistent asthmatic symptoms receiving either tiotropium (5 or 2.5 µg) or placebo once daily reporting AEs related to asthma exacerbations and symptoms plotted by month. Data from the Southern Hemisphere were shifted by 6 months (July = Month 1, January = Month 7) to align the seasonal time periods based on meteorological definitions. Patients were recruited and commenced the trial treatment periods across all months of the year. AE adverse event. From ref. 41. Copyright © 2019. Reprinted with permission.
